Activating mutations of the genes for NRAS and BRAF, components of the p44/42 mitogen-activated protein kinase (MAPK) pathway, are common findings in melanoma. Recent evidence in several nonmelanoma cell systems supports the regulation of the inducible nitric oxide synthase (iNOS) gene by this pathway. On the basis of our data showing that melanoma iNOS expression predicts shortened patient survival, we formulated the hypothesis that activating mutations of NRAS or BRAF, which lead to constitutive activation of the p44/42 MAPK pathway, drive iNOS expression in human melanoma. In the present study, we have shown that inhibition of melanoma iNOS activity by S-methylisothiourea leads to decreased cell proliferation, confirming the importance of iNOS activity for melanoma cell growth. Regulation of melanoma iNOS expression by the p44/42 MAPK pathway was demonstrated by inhibition of the pathway by U0126, and by BRAF RNA interference. To explore this regulatory pathway in human tissue, 20 melanoma tumors were examined for NRAS and BRAF mutations, immunohistochemical evidence of ERK phosphorylation, and iNOS expression. A significant association was found among these three features. We conclude that in human melanoma, activating mutations of NRAS and BRAF drive constitutive iNOS expression and, implicitly, nitric oxide production, contributing to the poor survival of these patients.
Introduction
Activating mutations of signal transduction proteins are associated with malignant transformation in a variety of cancers. In the case of melanoma, somatic mutations of either NRAS or BRAF are found in a majority of cases. The proto-oncogene NRAS is mutated in 20-30% of melanomas, the most common site being codon 61 located in exon 2 (Demunter et al., 2001; Omholt et al., 2002) . Mutations in NRAS codons 12 and 13 (exon 1) are also seen, albeit less frequently. NRAS encodes a membrane-associated protein involved in signal transduction in response to extracellular stimuli, functioning in part through activation of the p44/42 mitogenactivated protein kinase (MAPK) pathway. Found even more frequently in melanomas are mutations of BRAF, another component of the MAPK signaling cascade. Activating BRAF mutations have been reported in roughly 30-60% of melanomas, the most common being in the activation domain of exon 15, consisting of T1799A (V600E) (Davies et al., 2002; Gorden et al., 2003; Mercer and Pritchard, 2003; Yazdi, 2003) . Various mutations in exon 11 have been reported as well (Brose et al., 2002; Gorden et al., 2003) . B-Raf, which is a target of activated N-Ras, phosphorylates and activates MEK, which in turn activates the p44/42 MAPK (also known as extracellular signal-regulated kinase 1/2 or ERK). Phosphorylated ERK (pERK) targets a variety of transcription factors involved in the regulation of critical cellular functions and has been shown to play an important role in melanoma proliferation and survival (Smalley, 2003) .
The discovery of these activating mutations of the MAPK pathway has generated considerable interest in potential melanoma-specific targets downstream of pERK. Recently, several laboratories have reported a correlation between ERK activation and expression of inducible nitric oxide synthase (iNOS) in various nontransformed cells of human, rat, and murine origin (Kristof et al., 2001; Bhat and Fan, 2002; Liu et al., 2002; Jaramillo et al., 2003; Jiang et al., 2004) . This cytokine-inducible enzyme is one of the three known nitric oxide synthases, which produce nitric oxide (NO) through the conversion of arginine to citrulline. NO is a bioactive molecule with a diverse array of activities, playing roles in the regulation of vascular tone, immunity, inflammation, and apoptosis, and supporting the malignant phenotype in many forms of cancer (Wink and Mitchell, 2003; Tang and Grimm, 2004) . The ability of NO to promote cancer growth varies from one tumor type to the next and likely represents a complex balance between tumor promoting activities, such as induction of angiogenesis and protection from apoptosis, and tumoricidal effects, such as enhancement of dendritic cell activity (Jenkins et al., 1995; Perrotta et al., 2004) . In melanoma, the tumorigenic properties of NO appear to dominate, based on several lines of evidence. First, endogenous tumor NO has been shown to protect melanoma cells from apoptosis (Salvucci et al., 2001; Zheng et al., 2004) . Second, iNOS is constitutively expressed by cultured melanoma cells and is present in over 60% of human melanoma tumors (Ekmekcioglu et al., 2000; Massi et al., 2001; Ekmekcioglu et al., 2003) . Finally, for individuals with Stage III melanoma, the presence of iNOS within the tumor correlates strongly with poor patient survival (Ekmekcioglu et al., 2000) .
Given the association of pERK and iNOS in other systems, and the fact that both ERK activation and iNOS expression enhance melanoma tumor survival, we hypothesized that the iNOS gene lies downstream of the p44/42 MAPK pathway in human melanoma, thus connecting activating mutations of NRAS and BRAF with constitutive iNOS expression and aggressive tumor behavior. In the present study, we have explored this hypothesis in cultured human melanoma cells and preserved human melanoma tumor samples, and present herein our data demonstrating that melanoma iNOS is regulated by the p44/42 MAPK pathway.
Results
Inhibition of iNOS leads to melanoma growth inhibition S-methylisothiourea (SMT) is a competitive inhibitor of nitric oxide synthases, with a relative selectivity for iNOS (Szabo et al., 1994) . To examine the effects of iNOS inhibition on melanoma proliferation, the human melanoma cell lines WM793 and WM35 were treated with SMT at concentrations ranging from 0 to 4 mM. A 24 h exposure to SMT resulted in dose-dependent growth inhibition of the melanoma cells (Figure 1a ). This decrease in proliferation was partially reversed by coincubation with the nitric oxide donor DETA (Figure 1b) , indicating that the observed growth inhibition was, at least in part, mediated by a decline in iNOS-dependent nitric oxide production. Similar results were obtained with WM793 cells when the experiments were repeated with the iNOS inhibitor 1400W (Supplementary Figure 1) .
Melanoma iNOS expression is regulated by the p44/42 MAPK pathway The p44/42 MAPK signaling cascade is a critical pathway for melanoma proliferation, and has been shown to regulate iNOS in a number of in vitro nonmelanoma cell systems. Having demonstrated that iNOS activity is required for optimal melanoma cell growth, we asked whether melanoma iNOS was regulated by the p44/42 MAPK pathway. The two melanoma cell lines utilized for these experiments, WM793 and WM35, carry the activating T1799A (V600E) BRAF mutation. Consequently, both lines have constitutive MAPK pathway activation and baseline levels of pERK; they also constitutively express iNOS (Supplementary Figure 2) . The experimental approach was taken to inhibit the activated MAPK pathway in these cells and examine the downstream effects on iNOS. The first set of experiments utilized the MEK inhibitor U0126, a compound that inhibits the phosphorylation and activation of ERK by MEK. The inhibitor was placed on the cells for up to 72 h, and was replenished every 12 h. Exposure of WM793 and WM35 cells to U0126 resulted in a rapid decrease in ERK phosphorylation, followed by in a decline in iNOS protein levels (Figure 2 ). The kinetics of iNOS regulation differed between the two cell lines. In WM793, ERK phosphorylation recovered quickly, suggesting an alternative pathway able to bypass MEK inhibition, whereas pERK was virtually undetectable in WM35 for the entire exposure period. Regardless, after 48 h of U0126 incubation, iNOS expression was markedly diminished in both lines. Inhibition of iNOS expression did not occur when cells were treated under the same conditions with DMSO alone, the solvent for U0126 (data not shown).
BRAF RNA interference was next performed to confirm the above findings. WM793 cells were transfected with BRAF siRNA, and examined for B-Raf knockdown and effects on iNOS expression after 48 h. As shown in Figure 3a , when B-Raf protein levels were reduced to roughly 30% of baseline, iNOS levels were markedly diminished. ERK phosphorylation was also decreased, as expected, without a change in the amount of total ERK. Proliferation of WM793 cells transfected with BRAF siRNA was decreased compared to mock transfected control cells (Unt) or cells transfected with nontargeting (NT) siRNA (Figure 3b) , the difference between 'BRAF and 'NT' approaching significance (P ¼ 0.076). Taken together, these experiments indicate direct regulation of iNOS expression by the p44/42 MAPK pathway in melanoma cells.
NRAS and BRAF mutations are associated with iNOS expression in melanoma tissues
On the basis of the experiments described above, we predicted that human melanomas with constitutive activation of the p44/42 MAPK pathway secondary to N-Ras or B-Raf mutations would be more likely to express iNOS. To test this hypothesis, we collected 20 formalin-fixed paraffin-embedded tumors samples, consisting of five primary melanomas and 15 lymph node metastases. The cases were chosen on the basis of either strong iNOS immunostaining (n ¼ 13) or complete absence of iNOS expression (n ¼ 7) in previous IHC experiments; these numbers reflect published frequencies of melanoma iNOS expression (Ekmekcioglu et al., 2000; Massi et al., 2001; Ekmekcioglu et al., 2003) . DNA was extracted from these paraffin-embedded tissues and analysed for mutations of NRAS exon 1, NRAS exon 2, BRAF exon 11, and BRAF exon 15, which are the known sites of activating mutations. Overall, 12 of the 20 samples (60%) were found to carry an activating heterozygous point mutation in one of the exons examined (Table 1) . Four of these (20%) were found in NRAS codon 61 (exon 2). Activating BRAF mutations were found in eight tumors (40%), all occurring exon 15, consisting of the well-described T1799A mutation. No samples carried concomitant NRAS and BRAF mutations. Of note, one BRAF exon 15 mutant carried a second mutation in BRAF exon 11, consisting of G1328A, which has not been described previously.
Our hypothesis predicted that tumors with activating mutations of NRAS or BRAF would have constitutive ERK phosphorylation and, consequently, iNOS expression; those tumors without mutations should be negative for pERK and negative for iNOS. To test this hypothesis, the 20 melanoma samples were categorized as having any mutation or no mutation, and examined for the presence or absence of immunoreactivity for 
Discussion
We have examined the role of the p44/42 MAPK pathway in the regulation of melanoma iNOS, and have made two significant observations. First, using the iNOS inhibitor SMT and the NO donor DETA, we have shown that iNOS activity is required for optimal melanoma cell proliferation. The implication of this finding is that NO, the product of iNOS, promotes melanoma growth. These findings are consistent with published data demonstrating that endogenous NO protects melanoma cells from apoptosis (Salvucci et al., 2001) . We propose that additional mechanisms may contribute to the role of NO in melanoma tumorigenesis. Reaction of NO with oxygen or superoxide leads to the formation of intracellular reactive nitrogen oxide species which participate in the nitration and oxidation of critical cell proteins and nucleic acids, potentially interfering with the activity of tumor suppressor proteins and genes (Wink and Mitchell, 1998) . Furthermore, nitric oxide can react directly with metalloprotein complexes, such as the heme-iron moieties of guanylate cyclase and cytochrome P450, altering the activities of these proteins (Wink and Mitchell, 1998) . Numerous other possibilities exist, in keeping with the multitude of functions attributable to nitric oxide. Deciphering the mechanisms by which this molecule promotes melanoma growth is currently a major focus of our laboratory.
The second major finding of this study is the regulation of melanoma iNOS expression by the p44/ 42 MAPK pathway, shown by experiments utilizing the chemical inhibitor U0126, as well as by BRAF RNA interference. The importance of the p44/42 MAPK pathway in melanoma proliferation has been well documented, although effector molecules downstream of ERK have not been identified (Smalley, 2003) . Evidence for the iNOS gene as a downstream target of this pathway has been demonstrated previously in a number of in vitro systems, including cytokine-treated human lung epithelial cells, rat vascular smooth muscle cells, and murine macrophages; human astroglial cells exposed to HIV-1; and rat microglial cells infected with adenovirus (Kristof et al., 2001; Bhat and Fan, 2002; Liu et al., 2002; Jaramillo et al., 2003; Jiang et al., 2004) . The notable difference in the melanoma system is that iNOS induction appears to be the consequence of a constitutively active, mutation-driven MAPK pathway, rather than secondary to extrinsic factors. Our results with the melanoma cell lines led to the prediction that tumors with activating NRAS or BRAF mutations, driving the MAPK pathway, should be more likely to express iNOS. In fact, that was precisely our finding upon examination of the 20 human tumor samples. We have previously reported significantly shortened survival for Stage III melanoma patients whose tumors express iNOS. We now hypothesize that iNOS expression in these aggressive tumors is driven by NRAS or BRAF mutations in the majority of cases, a proposal that is currently being tested prospectively using melanoma patient material. In spite of the demonstrated connection between MAPK activation and iNOS expression, the events that lie in between remain largely unknown. The large, complex iNOS promoter is known to contain binding sites for activator protein-1 (AP-1), nuclear factor-kB (NF-kB), interferon regulatory factor-1 (IRF-1), signal transducer and activator of transcription-1a (STAT-1a), cAMP-responsive element binding protein (CREB), and CCAAT-enhancer box binding protein (C/EBP), to name a few (Kleinert et al., 2003) . Indeed, evidence exists in several cell types for the involvement of NF-kB in mediating the regulation of iNOS by ERK, and these findings may be relevant to melanoma (Kristof et al., 2001; Liu et al., 2002; Jiang et al., 2004) . However, other pathways and transcription factors that are relatively more specific to melanoma should also be explored. One such factor is the octamer (OCT)-binding protein BRN-2, which is expressed by melanoma cells in response to ERK activation and is associated with melanoma proliferation and survival (Goodall et al., 2004) . The iNOS promoter contains an OCT binding site and can be activated in vitro by BRN-3, another member of the OCT family (Gay et al., 1998) . The ability of BRN-2 to activate the iNOS promoter is not known, but represents a potentially unique intermediary between the MAPK pathway and iNOS in melanoma cells. An additional hypothetical mechanism to be explored is based on the inhibition of iNOS expression by physiologic levels of nitric oxide, that is, those produced by eNOS and nNOS. The low levels of nitric oxide produced by these enzymes suppress the transcriptional activation of the iNOS promoter by NF-kB (Park et al., 1997; Colasanti and Suzuki, 2000) . Although little is known regarding the expression of eNOS and nNOS in melanoma cells, downregulation of their expression by the MAPK pathway would be another mechanism for iNOS induction.
Finally, as an incidental finding, we discovered in one melanoma sample a novel mutation of BRAF exon 11, consisting of G1328A, leading to R443Q; since completing this study, we have found an identical mutation in a second melanoma tumor. The consequence of this mutation is the replacement of the basic amino-acid arginine in position 443 with the uncharged amino-acid glutamine. Similar mutations have been described in a melanoma (K438Q) and in a lung adenocarcinoma (K438T), each case replacing a basic amino acid (lysine) with an uncharged amino acid (glutamine or threonine) (Brose et al., 2002) . Position 443, near the beginning of the third conserved region (CR3), is located in an area containing critical BRAF regulatory sequences (Figure 5) . Downstream lies Ser 445, which is constitutively phosphorylated, as well as negatively charged Asp 447 and Asp 448, all of which are required for the high basal kinase activity of B-Raf (Mason et al., 1999) . It is possible that the loss of the positively charged arginine in the R443Q mutation enhances the otherwise negatively charged local environment, further increasing this basal activity. Alternatively, Threonine 439, four aminoacids upstream, represents a consensus Akt phosphorylation site. Akt activity has been suggested at this site, and Akt phosphorylation of two other sites, Ser 364 and Ser 428, clearly moderates B-Raf activity (Guan et al., 2000) . Thus, it is possible that R443Q may interfere with Akt phosphorylation of Thr 439, negating the Akt inhibitory effects. The determination of whether R443Q is indeed an activating mutation and the mechanism by which the activation occurs would add to the growing literature on the contribution of B-Raf mutations to tumorigenesis.
In conclusion, we have demonstrated a statistically significant association between the mutation-driven p44/ 42 MAPK pathway and the expression of iNOS in melanoma patient tumor samples, as well as evidence for direct functional regulation in cultured cells. These data support ongoing efforts in the development of therapeutic interventions directed to this pathway and in further research into the signaling molecules that tie the p44/42 MAPK pathway to iNOS.
Materials and methods

Cell lines
The human melanoma cell lines WM793 and WM35 were kindly provided by Dr Robert Kerbel (Sunnybrook Health Science Center, Toronto, ON, Canada). Cells were grown in RPMI medium supplemented with 10% fetal bovine serum.
Patient material
Sections of human melanoma tissue were obtained from the MD Anderson Cancer Center (MDACC) Melanoma Tumor Bank. Procurement of all patient material was conducted with MDACC IRB approval and in accordance with HIPAA regulations.
Reagents SMT and 1400W were purchased from Calbiochem (LaJolla, CA, USA), DETA from Alexis Biochemical (Carlsbad, CA, USA), and U0126 from Cell Signaling Technology (Beverly, MA, USA). Antibodies to iNOS and B-Raf for Western blotting were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA); iNOS antibodies used in IHC were purchased from Transduction Laboratories (San Jose, CA, USA); antibodies to total and phosphorylated ERK were purchased from Cell Signaling Technology.
Proliferation assays
Cells were plated at a density of 3 Â 10 4 per chamber of a twochamber tissue culture slide. The following day, media containing the iNOS inhibitor was placed on the cells; in experiments utilizing both iNOS inhibitor and DETA, the two compounds were added simultaneously. Effects on proliferation were examined after 24 h, by means of a commercially available BrdU immunocytochemistry assay (BrdU Staining Kit, Zymed, Carlsbad, CA, USA). BrdU labeling reagent (Zymed) was added at a 1:100 dilution to the cultures the evening before the assay. On the following day, the cells were fixed with 70% ethanol and incubated in 3% H 2 O 2 in methanol to block endogenous peroxidase activity. After permeabilization and blocking, the cells were incubated with biotinylated anti-BrdU antibody, followed by streptavidin peroxide, the chromogen diaminobenzidine (DAB), and a hematoxylin counterstain. To calculate the percentage of cells positive for BrdU, the stained sections were examined for brown DAB-stained nuclei. A minimum of 100 cells was counted from two different areas of the slide, and the mean and standard deviation calculated from these counts.
RNA interference BRAF-specific and NT control siRNA were purchased from Dharmacon (Lafayette, CO, USA). One day before siRNA transfection, cells were plated at a density of 1 Â 10 5 per well of a six-well plate, to achieve roughly 50% confluence. Just before transfection, growth media on the cells was replaced with 800 ml of Opti-MEM media (Gibco, Rockville, MD, USA). The siRNA was prepared at a stock concentration of 20 pmol/ml. For each well, 10 ml of siRNA was further diluted in 175 ml of Opti-MEM media. Subsequently, for each well, 3 ml of Oligofectamine Reagent (Invitrogen, Carlsbad, CA, USA) was combined with 12 ml of Opti-MEM media. After 10 min, the siRNA and Oligofectamine solutions were combined and incubated at room temperature for 20 min. The mixture was then added to the media already present on the cells, giving a final siRNA concentration of 200 nM in a volume of 1 ml. After 5 h, 1 ml of growth media was added to the transfection media, and after 24 h, the media was completely exchanged for growth media. Cell lysates were prepared 48 h after transfection.
Western blotting
Proteins extracted from cell lysates were separated by SDSpolyacrylamide gel electrophoresis (SDS-PAGE), transferred to a nitrocellulose membrane, and blocked for 1 h in 5% dry milk/PBS. Incubation with primary antibody diluted in 5% dry milk/PBS/ 0.1% Tween was performed overnight at 41C, followed by a 1 h incubation with horseradish peroxidase labeled secondary antibody, diluted in 5% dry milk/PBS/ 0.1% Tween. The membrane was developed using enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
DNA extraction from paraffin-embedded tumor sections Sections of formalin-fixed paraffin-embedded melanoma tumors were used as a source of DNA. Between one and four 5 mm sections were used per sample, and only sections containing a minimum 30% tumor were included. Each tumor sample was scraped with a sterile scalpel blade from the glass slide into xylenes and left overnight for deparaffinization. On the following day, the tissue pellet was washed twice with 100% ethanol. DNA was extracted using the DNeasy Tissue Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. 
PCR
DNA sequencing
Sequencing of PCR products was performed by the MDACC DNA Core Facility using an ABI Prism 3100 DNA Genetic Analyzer (Applied Biosystems), using Big Dyes v.3.1 dye terminator chemistry (Applied Biosystems). Forward and reverse DNA strands were sequenced for all samples.
Immunohistochemistry
Tissue sections were deparaffinized in xylenes, and rehydrated in graded concentrations (100-85%) of ethanol. Sections were placed in Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA, USA) and microwaved intermittently for a total of 10 min, to maintain boiling temperature. After cooling, the slides were placed in 3% H 2 O 2 in cold methanol for 15 min to block endogenous peroxidase activity. This step was followed by permeabilization with 0.05% Triton X-100 (Sigma, St Louis, MO, USA) in phosphate-buffered saline for 15 min. An avidin-biotin-peroxidase complex (ABC) kit (Vectastain, Vector Laboratories) was then used for antigen detection. After a 30-min incubation with blocking serum, the primary antibody was applied and incubated for 2 h at room temperature. The slides were then washed, incubated for 30 min with secondary biotinylated antibody, followed by a 30-min incubation with the ABC reagent. The immunolabeling was developed with the chromogen 3-amino-9-ethylcarbazole. Hematoxylin was applied as a counter stain. Immunoreactivity was evaluated by two independent observers.
Statistical analysis
Unpaired, two-sided t-tests were used to examine differences in BrdU uptake in proliferation assays. Associations between mutations, ERK phosphorylation, and iNOS expression in tumor samples were tested for significance by means of w 2 analysis. In all cases, significance was set at a P-value of 0.05. expert DNA sequencing; Drs A Hafeez Diwan and Victor Prieto for assistance in interpretation of immunohistochemistry data; and Lihong Long, Anita Myer, Sandra Kinney, Sandra Yekell, and Sandra Ortega-Mendez for technical advice and contributions.
